RxDoctor Payments Data

Eric Swanson, MD

Anatomic Pathology & Clinical Pathology · Salt Lake City, UTNPI 1548580756

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (54.1%), speaking fees and education — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by AstraZeneca at 46.9% of the total. Reporting peaked in 2019 at $882 and has fallen 72.9% since, to $239 in 2024.

$1,624in general payments, 2019–2025

Across 26 payments — averaging $62.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$761
  • Blueprint Medicines Corporation$244
  • Johnson & Johnson$164
  • Merck$163
  • Bayer$63
  • AMAG Pharmaceuticals, Inc.$45
  • plus $184 from 8 others

What the payments were for

  • Speaking & faculty fees$70043%
  • Food & beverage$87954%
  • Education$453%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,624 in reported general payments places this provider in the 85th percentile of 57 anatomic pathology & clinical pathology providers in Utah.

See all anatomic pathology & clinical pathology providers in Utah

Medicare billing

Part B allowed, 2024
$197,107
Medicare patients
1,373
Services billed
3,971

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other anatomic pathology & clinical pathology in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →